Highest-materiality recent filing
$4.9M convertible promissory note, 12-month term, no interest, 5% OID, convertible at discount to market.
NWBO refutes false rumors of MHRA rejection; MHRA confirms DCVax-L MAA still under review
MHRA confirmed DCVax-L MAA for glioblastoma remains under initial review, not refused, withdrawn, or appealed.
Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.
NWBO settles 2020 option litigation; insurer pays $2.25M, 17% options cancelled
Settlement agreement entered Dec 12, 2025 for litigation over 2020 option awards.
NWBO shareholders OK share increase to 2.6B, elect Pat Sarma
Authorized common shares increased from 1.7B to 2.6B; 89.65% of votes cast in favor.
NWBO enters $5M convertible note with Yorkville for Sawston facility
Promissory note of $5M with YA II PN, Ltd. (Yorkville) for 12 months, no payments due until maturity.
NW Biotherapeutics enters $5.5M loan agreement with Streeterville Capital
Loan amount $5,505,000; maturity 22 months; interest 8% p.a.; 10% original issue discount.
NWBO closes Advent BioServices acquisition; pays £1.4M + AP over 2 years; 19M securities revert
Acquisition of Advent BioServices closed; Advent becomes wholly owned subsidiary.
NWBO files new Form S-3 shelf registration to replace expiring registration on Oct 25, 2025
Filed new S-3 shelf registration on October 23, 2025, effective for three years.
Northwest Biotherapeutics settles shareholder litigation over 2020 options; insurers to pay $2.25M
Settlement resolves Delaware Chancery litigation over 2020 option awards to management and directors.
Northwest Biotherapeutics announces $5M convertible note and $50M standby equity facility
Entered $5M convertible promissory note with Yorkville, 13-month term, 7% original issue discount, no interest.
Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity
Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.
NW Bio investigates social media rumors; MHRA MAA review continues
Company probing rumors linked to parties in federal NY lawsuit; coinciding with stock market developments.
NWBO annual meeting re-elects directors, ratifies auditor and option awards, approves exec comp
Re-elected Dr. Alton L. Boynton (94.04% for) and Ambassador J. Cofer Black (93.01% for) as Class I directors for three-year terms.
Northwest Biotherapeutics sells 8.125M shares at $0.40 to SIO Capital for $3.25M
SPA signed June 4, 2024; closing expected June 5, 2024.
Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital
Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.
Northwest Biotherapeutics appoints Pat Sarma as Class II director effective March 18, 2024
Pat Sarma appointed as Class II director and to Audit, Compensation, and Conflicts Committees.
Director Jerry Jasinowski retires from Northwest Biotherapeutics Board at age 85
Jerry Jasinowski retired from Board on March 8, 2024, after more than a decade of service.
NWBO enters $11M loan with Streeterville Capital; 8% interest, 24-month maturity
Loan amount $11,005,000 from Streeterville Capital; 24-month maturity; repayments begin Nov 2024.
Northwest Biotherapeutics secures $11M loan from Streeterville Capital
Loan of $11,005,000 from Streeterville Capital, maturity 22 months, repayments start Nov 2023.
Northwest Biotherapeutics increases authorized common shares from 1.2B to 1.7B
Filed Certificate of Amendment with Delaware Secretary of State on January 9, 2023.
Northwest Biotherapeutics shareholders approve all six proposals at 2022 annual meeting
Re-elected directors Linda F. Powers and Navid Malik with 97.2% and 97.5% of votes cast respectively.
NWBO eliminates Series A/B Preferred, creates Series C Preferred (10M shares)
Filed Certificate of Elimination for Series A and B Preferred Stock on July 20, 2022; no shares outstanding.
NWBO enters $15M loan with Streeterville; conversion right tied to Phase III data
Net proceeds of $15M from Streeterville Capital, LLC; 22-month maturity, 8% interest, 10% OID.
The Board appointed Pat Sarma as a Class II director on March 18, 2024, and also appointed him to the Audit, Compensation, and Conflicts Committees of the Board.
Mr. Jerry Jasinowski retired from the Board of Directors of Northwest Biotherapeutics, Inc. on March 8, 2024, after more than a decade of service on the Board.
Max materiality 0.75 · Median 0.53 · Most common event debt